bluuebunny/crossref_metadata_2025_split huggingface dataset:
The safety of cyclosporine and tacrolimus in pediatric nephrotic syndrome patients: a disproportionate analysis based on the FAERS database
Authors: Liu Yu , Yan Chong , Zhao Yaowang , Deng Sui , Zu Jiancheng 
Published: January 2025

ObjectiveThis study aimed to systematically evaluate the safety of cyclosporine (CsA) and tacrolimus (TAC) in pediatric nephrotic syndrome (NS) patients using real-world data from the FDA Adverse Event Reporting System (FAERS).MethodsWe analyzed adverse event (AE) reports from the FAERS database between Q4 2003 and Q2 2024, focusing on AEs associated with CsA and TAC in NS patients aged 18 years and younger. We employed three signal detection methods—Proportional Reporting Ratio (PRR), Relative Reporting Ratio (RRR), and Reporting Odds Ratio (ROR)—to assess the risk of drug-related AEs. Sensitivity analyses were conducted to explore the influence of gender on AE occurrence.ResultsA total of 207 CsA-related and 145 TAC-related AE reports were included. CsA was significantly associated with nephropathy toxic (ROR = 8.26, 95% CI: 4.21–16.20), urine output decreased (ROR = 29.93, 95% CI: 3.66–244.61), and posterior reversible encephalopathy syndrome (ROR = 6.70, 95% CI: 3.17–14.14). TAC was associated with an increased risk of dystonia (ROR = 67.93, 95% CI: 8.63–534.86), kidney fibrosis (ROR = 22.65, 95% CI: 8.16–62.87), and diabetic ketoacidosis (ROR = 46.51, 95% CI: 5.68–380.97). Sensitivity analysis indicated that gender influenced the occurrence of AEs, with CsA showing higher nephrotoxicity in male patients, while TAC was more strongly associated with metabolic disorders and neurological AEs in female patients.ConclusionIn pediatric NS patients, CsA primarily induces nephrotoxicity and neurological complications, whereas TAC is more likely to cause kidney fibrosis and metabolic disorders. Enhanced monitoring of these AEs and individualized drug adjustments based on patient characteristics are recommended to optimize treatment outcomes and reduce AE incidence.
Prenatal ultrasound phenotype of fetuses with recurrent 1q21.1 deletion and duplication syndrome
Authors: Wang Fengyang , Peng Huijuan , Lou Guiyu , Ren Yanxin , Liao Shixiu 
Published: January 2025

ObjectiveOur study aimed to collect fetuses with recurrent 1q21.1 deletion or duplication syndrome for systematic clinical phenotype analysis to further delineate the intrauterine phenotype features of the two reciprocal syndromes.MethodsPrenatal samples, including amniotic fluid and chorionic villus samples, were obtained by amniocentesis and chorionic villus sampling at our center, respectively. In total, 43 fetuses were diagnosed with recurrent 1q21.1 deletion or duplication syndrome via array comparative genomic hybridization (array CGH) or copy number variation sequencing (CNV-seq). Prenatal clinical data, pregnancy outcomes, and individual conditions after birth were collected.ResultsIn total, 20 fetuses were diagnosed with 1q21.1 deletion syndrome, and 11 had abnormal ultrasound findings. The most common ultrasound features were renal anomalies, musculoskeletal abnormalities, and increased NT. Other less common ultrasound findings encompassed neurologic abnormalities, cardiovascular defects, absence of the gallbladder, intrauterine growth retardation, and cervical cystic hygroma. On the other hand, 23 fetuses had reciprocal 1q21.1 duplication syndrome, 11 of which had abnormal ultrasound findings, mainly nasal bone abnormalities, cardiovascular defects, increased NT, and neurologic abnormalities.ConclusionsOur case study suggested that the prenatal clinical phenotypes of the recurrent 1q21.1 deletion syndrome and reciprocal duplication syndrome fetuses were highly diverse with incomplete penetrance. Additionally, our findings should expand the intrauterine phenotype associated with the recurrent 1q21.1 region by a series of prenatal ultrasonic anomalies in this work that were described for the first time, which might broaden knowledge of the genotype and phenotype correlation.
Translation and cross-cultural validation of the Lithuanian version of the sleep-related breathing disorder scale of the Pediatric Sleep Questionnaire
Authors: Oboleviciene Gintare , Miseviciene Valdone 
Published: January 2025

IntroductionSleep-disordered breathing (SDB) is considered the second most common chronic health condition in children. Untreated SDB is associated with long-term health consequences. Our objective was to translate the Pediatric Sleep Questionnaire (PSQ) into Lithuanian and culturally adapt and validate the translated version in order to improve the diagnosis of SDB in Lithuanian children.MethodsTranslations and cultural adaptations were performed to generate a Lithuanian version of the PSQ. Psychometric analysis was conducted on 112 Lithuanian children aged 2–17 years. All patients underwent overnight polysomnography.ResultsThe Lithuanian PSQ showed good internal consistency (Cronbach's alpha = 0.816). Lithuanian PSQ responses administered 14–30 days apart were strongly correlated (r = 0.924, p &lt; 0.001, 95% CI 0.830–0.967). EFA of the Lithuanian PSQ confirmed four factors (“snoring”, “behavior”, “sleepiness”, and “other”). We found a sensitivity of 72.7% and specificity of 64.6% for a Lithuanian PSQ cutoff score of 8 to predict moderate-to-severe apnea, and a sensitivity of 85.0% and specificity of 62.0% to predict severe apnea. Using a Lithuanian PSQ cutoff ratio of 0.4, a sensitivity of 72.7% and specificity of 63.3% were found to predict moderate-to-severe apnea, and a sensitivity of 85.0% and specificity of 60.9% were found to predict severe apnea.ConclusionsThe Lithuanian version of the PSQ is a reliable, validated, and culturally adapted screening tool for the prediction of moderate-to-severe sleep apnea in children aged 2–17 years. However, polysomnography should be performed to confirm the diagnosis of sleep apnea and other SDB, and to determine the degree of the disorder and the need for treatment.
Angiopoietin-like protein 4 dysregulation in kidney diseases: a promising biomarker and therapeutic target
Authors: Li Yan , Zhang Yuxin , Cao Mengxia , Yuan Tingting , Ou Santao 
Published: January 2025

The global burden of renal diseases is increasingly severe, underscoring the need for in-depth exploration of the molecular mechanisms underlying renal disease progression and the development of potential novel biomarkers or therapeutic targets. Angiopoietin-like protein 4 (ANGPTL4) is a multifunctional cytokine involved in the regulation of key biological processes, such as glucose and lipid metabolism, inflammation, vascular permeability, and angiogenesis, all of which play crucial roles in the pathogenesis of kidney diseases. Over the past 2 decades, ANGPTL4 has been regarded as playing a pivotal role in the progression of various kidney diseases, prompting significant interest from the scientific community regarding its potential clinical utility in renal disorders. This review synthesizes the available literature, provides a concise overview of the molecular biological effects of ANGPTL4, and highlights its relationship with multiple renal diseases and recent research advancements. These findings underscore the important gaps that warrant further investigation to develop novel targets for the prediction or treatment of various renal diseases.
Global research landscape and emerging trends of non-coding RNAs in prostate cancer: a bibliometric analysis
Authors: Zhou Yu-Liang , Yao Wen-Liang , Chen Sheng-Hui , Wang Peng , Fu Jing-Wen , Zhao Jia-Qin , Zhang Jia-Yi 
Published: January 2025

BackgroundProstate cancer (PC) is the most frequently diagnosed cancer in men and continues to be a major cause of cancer-related mortality worldwide. In recent years, non-coding RNAs (ncRNAs) have emerged as a significant focus in molecular biology research, playing a pivotal role in the development and progression of PC. This study employed bibliometric analysis to explore the global outputs, research hotspots, and future trends in ncRNA-related PC research over the past 20 years.MethodsPublications on PC-related ncRNAs from 2004 to 2023 were retrieved from Web of Science Core Collection. The co-operation network of countries, institutions, and authors on this topic was analyzed using CiteSpace (version 6.2. R6). In addition, co-occurrence analysis of keywords and co-citation analysis of references were performed using CiteSpace, and emergent detection was also performed.ResultsA total of 2,951 articles on PC-related ncRNAs were finally included in this study for analysis. China contributed the largest number of publications, while the United States was the most influential country in this field, with collaborative ties to 26 other countries. Fudan University was identified as the most active institution in this field. Rajvir Dahiya was the most prolific and influential author. Within the co-citation network, clusters labeled “EVs,” “circRNA,” and “ceRNA” represented current research directions. The cluster labeled “gene” dominated the co-occurrence keywords. “circRNA” showed the highest burst strength among keywords, with “circRNA,” “EVs” and “exosome” maintaining sustained burst strength, suggesting these are the emerging research frontiers in this field.ConclusionInvestigating ncRNAs as pivotal research subjects in PC is essential for addressing the public health impact of the disease and advancing innovative diagnostic and targeted therapeutic strategies. This study provides a comprehensive bibliometric analysis of research related to PC-associated ncRNAs, delivering a scientific perspective and identifying potential research directions for scholars in this field.
Research hotspots and frontiers of endoplasmic reticulum in glomerular podocytes: a bibliometric and visual analysis from 2005 to 2023
Authors: Junli Wang , Zhihong Hao , Lina Wang , Qiaoqun Ou , Jing Qu , Jiaqi Hu , Yu Shengyou 
Published: January 2025

BackgroundThe glomerular podocyte endoplasmic reticulum is a critical component in renal function, yet its research landscape is not fully understood. This study aims to map the existing research on podocyte endoplasmic reticulum by analyzing publications in the Web of Science Core Collection (WOSCC) from the past 19 years.MethodsWe conducted a bibliometric analysis using Citespace, VOSviewer, the Metrology Literature Online platform, and the Bibliometrix software package to visualize and interpret the data from WOSCC. The analysis focused on publication volume, authorship, institutional contributions, and research trends.ResultsThe analysis revealed a significant growth in publications, indicating a surge in interest in podocyte endoplasmic reticulum research. Cybulsky, Andrey V, and Papillon, Joan emerge as the most prolific authors, and the Journal of the American Society of Nephrology is the leading journal in this field. China is the top contributor in terms of publications, with McGill University being the most productive institution. The research primarily focuses on endoplasmic reticulum stress, diabetic nephropathy, and apoptosis, with emerging trends in “foot cell apoptosis,” “cell signaling pathways,” and “autophagy.”ConclusionThe findings highlight the expanding scope of podocyte endoplasmic reticulum research, with a particular emphasis on the mechanisms of endoplasmic reticulum stress and podocyte apoptosis. Future research directions may include the identification of specific therapeutic targets, detailed exploration of podocyte signaling pathways, and the role of autophagy. This study provides a comprehensive overview of the major research areas, frontiers, and trends in podocyte endoplasmic reticulum research, which are pivotal for guiding future investigations.
Efficiency and safety of HAIC combined with lenvatinib and tislelizumab for advanced hepatocellular carcinoma with high tumor burden: a multicenter propensity score matching analysis
Authors: Zhao Zhonghua , Jiang Xiongying , Wen Shiping , Hao Yanzhang 
Published: January 2025

PurposeThe present work focused on assessing whether hepatic arterial infusion chemotherapy (HAIC) combined with lenvatinib and tislelizumab was safe and effective on advanced hepatocellular carcinoma (HCC) showing high tumor burden.MethodsIn the present multicenter retrospective study, treatment-naive advanced HCC patients (BCLC stage C) showing high tumor burden (maximum diameter of intrahepatic lesion beyond 7 cm) treated with lenvatinib and tislelizumab with or without HAIC were reviewed for eligibility from June 2020 to June 2023. Baseline differences between groups were mitigated by propensity score matching (PSM). Our primary endpoint was overall survival (OS); and secondary endpoints included adverse events (AEs), progression-free survival (PFS), disease control rate (DCR) and objective response rate (ORR) according to RECIST 1.1 criteria, respectively.ResultsAfter eligibility reviewed, total 162 patients treated with lenvatinib and tislelizumab were enrolled: 63 patients with HAIC (HTP group), and the remaining 99 patients without HAIC (TP group). After PSM 1:1, 47 cases were evenly divided into each group. Of them, HTP group showed significant prolonged median OS compared with TP group (16.6 versus 21.0 months; hazard ratio [HR]: 0.26, 95% confidence interval [CI]: 0.35–0.98; p = 0.039), and median PFS of HTP group was also prolonged (8.9 versus 11.6 months; HR: 0.55, 95% CI: 0.34–0.87; p = 0.010). Higher DCR and ORR could be observed in HTP relative to TP groups (ORR: 53.2% versus 17.0%, p &lt; 0.001; DCR: 87.2% versus 61.7%, p = 0.004). The severe AEs (grade 3/4) and all grades were comparable between the groups, while all of these AEs could be controlled, and AEs of grade 5 were not reported.ConclusionHAIC combined with lenvatinib and tislelizumab is the candidate treatment for advanced HCC patients because of its improved prognosis and acceptable safety.
Hepatotoxicity of statins: a real-world study based on the US Food and Drug Administration Adverse Event Reporting System database
Authors: Wang Bojing , Huang Shu , Li Shiqi , Deng Yaqi , Li Ziyan , Wang Yizhou , Shi Xiaomin , Zhang Wei , Shi Lei , Wang Xiaohong , Tang Xiaowei 
Published: January 2025

BackgroundStatins, as an important class of lipid-lowering drugs, play a key role in the prevention and treatment of cardiovascular diseases. However, with their widespread use in clinical practice, some adverse events have gradually emerged. In particular, the hepatotoxicity associated with statins use has become one of the clinical concerns that require sufficient attention.MethodsIn this study, we conducted a comprehensive and detailed analysis of the hepatotoxicity of statins based on the data of the US Food and Drug Administration Adverse Event Reporting System database from the first quarter (Q1) of 2004 to the Q1 of 2024 and used Reporting Odds Ratios and Empirical Bayes Geometric Mean to mine the signal of adverse events.ResultsIn this study, hepatic disorder related seven statins all exhibited positive signals. Through signal mining, we identified a total of 14,511 cases of adverse events associated with hepatic disorder caused by these statin drugs, with atorvastatin, simvastatin, and rosuvastatin occurring at a higher rate. A total of 148 positive signals related to adverse events of hepatic disorder were captured. Autoimmune hepatitis and drug-induced liver injury both presented positive signals across multiple statin drugs. Notably, atorvastatin had the most significant signal strength in cholestatic pruritus and bilirubin conjugation abnormal. Fluvastatin also showed notable signal strength in autoimmune hepatitis, while simvastatin had a relatively weaker signal strength for hepatic enzyme increased.ConclusionThis study discovered specific adverse event signal values, revealing potential hepatotoxic risks associated with the use of statin drugs. The results provide an important reference for the safe clinical use of drugs, help to improve the understanding of the safety of statins, and also provide a scientific basis for clinicians to make more accurate and safe decisions when making treatment plans.
A randomized sequential allocation study on the optimum programmed intermittent epidural boluses interval time with different concentrations of ropivacaine combined with the dural puncture epidural technique for labor analgesia
Authors: Mao Jingjing , Chen Yi , Sun Linsen , Xu Xiaoxiao , Xu Kai , Ren Tingting , Xiong Xiangsheng , Zhao Weibing 
Published: January 2025

BackgroundThe combined technique of programmed intermittent epidural boluses (PIEB) and dural puncture epidural (DPE) is currently considered a more effective mode for labor analgesia. We investigated the optimal interval time for PIEB administration with different concentrations of ropivacaine combined with the DPE for labor analgesia.MethodsNinety patients with cervical dilation of &lt;5 cm and a VAS score &gt;5 were randomly assigned to receive labor analgesia with ropivacaine at concentrations of 0.075% (0.075% group), 0.1% (0.1% group), and 0.125% (0.125% group). In each group, an initial administration of a combination of ropivacaine 12 mL and sufentanil 0.3 μg/mL was followed by an additional dose of ropivacaine 10 mL and sufentanil 0.3 μg/mL after 30 min. The initial PIEB interval time was set at 40 min for the first patient in each group, and subsequent interval times for the following patients were adjusted based on meeting analgesic needs (VAS score ≤1) with a gradient of 10 min. The primary outcome was the ED90 of interval time required to achieve analgesic needs during PIEB with different concentrations of ropivacaine, employing an up-and-down sequential allocation method.ResultsThe optimal PIEB interval times for ropivacaine concentrations of 0.075%, 0.1%, and 0.125% were determined to be 40.9 (95% CI, 35.3–45.8), 45.3 (95% CI, 39.3–51.5), and 52.9 (95% CI, 46.8–59.3) minutes respectively, while comparable maternal and neonatal outcomes were observed across all groups.ConclusionWhen PIEB is combined with DPE for labor analgesia, the optimal PIEB interval times for ropivacaine concentrations of 0.075%, 0.1%, and 0.125% were determined to be 41, 45, and 53 min respectively.
Cost-effectiveness of tyrosine kinase inhibitor treatment strategies for chronic myeloid leukemia in South Africa
Authors: Woudberg Rochelle , Sinanovic Edina 
Published: January 2025

BackgroundThe treatment of chronic myeloid leukemia through tyrosine kinase inhibitors (TKIs) has achieved promising efficacy and safety outcomes, however the costs are associated with a substantial economic burden. The objective of this study was to develop a Markov model with a 20-year time horizon to assess the cost effectiveness of TKIs from a public healthcare system perspective in South Africa.MethodsWe constructed a Markov model to compare three strategies in which treatment was initiated with either imatinib, nilotinib, or dasatinib. Treatment was switched to another TKI in the case of intolerance or resistance to the initial TKI. Effectiveness and utility data were obtained from published literature. Cost data was obtained from local sources for generic imatinib and branded second-generation TKIs and based on national tariffs. Outcomes were reported in total costs and quality-adjusted life years (QALYs). Outcomes were based on calculated incremental cost effectiveness ratios (ICERs) and compared to a willingness-to-pay (WTP) threshold. Sensitivity analyses were conducted to determine the robustness of the model outcomes.ResultsThe base-case results showed that imatinib was favored over nilotinib and dasatinib by having the lowest cost at $120 719.55 and providing 5.93 QALYs. Compared to imatinib strategy, nilotinib had an ICER of $26 620.27 per QALY and dasatinib had an ICER of $35 934.94 per QALY, both exceeding the WTP threshold of $18 760 per QALY gained. The sensitivity analysis indicated the robustness of the results.ConclusionImatinib remains the most cost-effective first-line treatment for adults diagnosed with CML in South Africa, with a high probability of being cost-effective across a range of WTP thresholds. Nilotinib and Dasatinib, though offering clinical benefits, their affordability remains a challenge within the current healthcare system and should remain reserved for second-line treatment.
The effect of instability resistance training on balance ability among athletes: a systematic review
Authors: Gao Jianxin , Fu Xinxin , Xu Hang , Guo Qi , Wang Xiaopeng 
Published: January 2025

BackgroundInstability resistance training (IRT) has been the focus of extensive research because of its proven benefits to balance ability, core stability, and sports performance for athletes. However, there is a lack of systematic reviews explicitly evaluating IRT’s impact on athletes’ balance ability. This study aims to conduct a systematic review of the effects of IRT on balance ability among athletes.MethodThis study used guidelines for the systematic review and meta-analysis of PRISMA, Web of Science, EBSCOhost (SPORTDiscus), PubMed, Scopus, and Google Scholar to collect original references in electronic databases. The PICOS method was selected for the inclusion criteria. The physiotherapy evidence database (PEDro) scale was used to assess the scoring for articles’ risk range of bias. The scoring of 20 studies ranges from 4–8, and study quality is moderate to high.ResultsOut of 285 identified studies, only 20 articles fulfilled all the eligibility criteria after screening. IRT could significantly improve reciprocal, static, and dynamic balance ability among judo athletes, basketball players, weightlifters, archery athletes, soccer players, rhythmic gymnasts, badminton players, track and field athletes, handball players, volleyball players, and gymnasts using unstable surfaces or environments (i.e., BOSU, Swiss, Wobble boards, Suspension trainer, Sissel pillows, Inflated disc and foam surface, Airex balance pad, Togu power ball, Thera-Band, Elastic band strap, Sand surface and so on).ConclusionThe finding suggests that different types of IRT benefit athletes as this training method can effectively enhance reciprocal, static, and dynamic balance ability in athletes. Therefore, this review suggests that IRT should be considered in athletes’ daily training routines for the physical fitness of reciprocal, static, and dynamic balance ability.
A combined diagnostic model including middle rectal artery visualization for predicting lateral lymph node metastasis in rectal cancer
Authors: Wang Ning , Li Yiping , Lu Kun , Wei Kaikai , Jia Shize , Fan Shuhong , Ren Donglin , Fu Yuanji , Liu Zhimin 
Published: January 2025

PurposeThis study attempted to establish a combined diagnostic model encompassing visualization of the middle rectal artery (MRA) and other imaging features to improve the diagnostic efficiency of lateral lymph node (LLN) metastasis, which is crucial for clinical decision-making in rectal cancer.MethodOne hundred eleven patients receiving bilateral or unilateral lymph node dissection were enrolled, and 140 cases of LLN status on a certain unilateral pelvic sidewall were selected. Enhanced computed tomography (CT) was used to determine whether MRA was visible. Multivariable regression was used to establish a diagnostic model combining MRA visualization with other imaging features to predict LLN metastasis. Receiver operating characteristic (ROC) curve and area under the ROC curve (AUC) were used to test the diagnostic efficacy for LLN metastasis. Ten-fold cross-validation was completed to internally validate the diagnostic model.ResultsOf the 140 LLNs harvested from 111 patients, 76 were positive and 64 were negative for metastases, respectively. The diagnostic model combining the MRA visualization and lymph node short diameter showed a greater efficiency than a single scale (AUC = 0.945, 95% confidence interval = 0.893–0.976, P &lt; 0.001). The mean cross-validated AUC was 0.869 (95% confidence interval = 0.835–0.903).ConclusionOur results establish a combined diagnostic model with the help of MRA visualization to yield a high diagnostic efficiency of LLN metastasis in rectal cancer.